185 related articles for article (PubMed ID: 11006766)
1. Population-based fecal occult blood screening for colon cancer: will the benefits outweigh the harm?
Marshall KG
CMAJ; 2000 Sep; 163(5):545-6; discussion 547. PubMed ID: 11006766
[No Abstract] [Full Text] [Related]
2. One-time screening for colorectal cancer with combined fecal occult-blood testing and examination of the distal colon.
Lieberman DA; Weiss DG;
N Engl J Med; 2001 Aug; 345(8):555-60. PubMed ID: 11529208
[TBL] [Abstract][Full Text] [Related]
3. Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics.
Allison JE; Sakoda LC; Levin TR; Tucker JP; Tekawa IS; Cuff T; Pauly MP; Shlager L; Palitz AM; Zhao WK; Schwartz JS; Ransohoff DF; Selby JV
J Natl Cancer Inst; 2007 Oct; 99(19):1462-70. PubMed ID: 17895475
[TBL] [Abstract][Full Text] [Related]
4. Colorectal cancer screening: now is the time.
Winawer SJ; Zauber AG
CMAJ; 2000 Sep; 163(5):543-4; discussion 548. PubMed ID: 11006765
[No Abstract] [Full Text] [Related]
5. Many participants in fecal occult blood test population screening have a higher-than-average risk for colorectal cancer.
Worthley DL; Smith A; Bampton PA; Cole SR; Young GP
Eur J Gastroenterol Hepatol; 2006 Oct; 18(10):1079-83. PubMed ID: 16957514
[TBL] [Abstract][Full Text] [Related]
6. Nonmedical costs of colorectal cancer screening with the fecal occult blood test and colonoscopy.
Heitman SJ; Au F; Manns BJ; McGregor SE; Hilsden RJ
Clin Gastroenterol Hepatol; 2008 Aug; 6(8):912-917.e1. PubMed ID: 18534918
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of colorectal cancer screening with computed tomography colonography or fecal blood tests.
Heresbach D; Chauvin P; Grolier J; Josselin JM
Eur J Gastroenterol Hepatol; 2010 Nov; 22(11):1372-9. PubMed ID: 20802341
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of mass screening for colorectal cancer: choice of fecal occult blood test and screening strategy.
Sobhani I; Alzahouri K; Ghout I; Charles DJ; Durand-Zaleski I
Dis Colon Rectum; 2011 Jul; 54(7):876-86. PubMed ID: 21654256
[TBL] [Abstract][Full Text] [Related]
9. Fecal occult blood testing when colonoscopy capacity is limited.
Wilschut JA; Habbema JD; van Leerdam ME; Hol L; Lansdorp-Vogelaar I; Kuipers EJ; van Ballegooijen M
J Natl Cancer Inst; 2011 Dec; 103(23):1741-51. PubMed ID: 22076285
[TBL] [Abstract][Full Text] [Related]
10. A population-based estimate of the extent of colorectal cancer screening in Ontario.
Rabeneck L; Paszat LF
Am J Gastroenterol; 2004 Jun; 99(6):1141-4. PubMed ID: 15180738
[TBL] [Abstract][Full Text] [Related]
11. Immunochemical fecal occult blood testing is equally sensitive for proximal and distal advanced neoplasia.
de Wijkerslooth TR; Stoop EM; Bossuyt PM; Meijer GA; van Ballegooijen M; van Roon AH; Stegeman I; Kraaijenhagen RA; Fockens P; van Leerdam ME; Dekker E; Kuipers EJ
Am J Gastroenterol; 2012 Oct; 107(10):1570-8. PubMed ID: 22850431
[TBL] [Abstract][Full Text] [Related]
12. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population.
van Rossum LG; van Rijn AF; Laheij RJ; van Oijen MG; Fockens P; van Krieken HH; Verbeek AL; Jansen JB; Dekker E
Gastroenterology; 2008 Jul; 135(1):82-90. PubMed ID: 18482589
[TBL] [Abstract][Full Text] [Related]
13. [Arguments against implementing a population-based screening programme for colorectal cancer].
Bonneux L
Ned Tijdschr Geneeskd; 2008 Aug; 152(32):1777. PubMed ID: 18754310
[TBL] [Abstract][Full Text] [Related]
14. Colorectal cancer screening through detection of fecal occult blood in a controlled health zone.
Tárraga P; García-Olmo D; Celada A; García-Molinero Mf; Divison JA; Casado C
Rev Esp Enferm Dig; 1999 May; 91(5):335-44. PubMed ID: 10362875
[TBL] [Abstract][Full Text] [Related]
15. [Colorectal cancer screening should be evaluated in Swedish studies].
Blom J
Lakartidningen; 2008 Sep 17-23; 105(38):2564-7. PubMed ID: 18846858
[No Abstract] [Full Text] [Related]
16. Quantitative immunochemical fecal occult blood testing for colorectal adenoma detection: evaluation in the target population of screening and comparison with qualitative tests.
Haug U; Hundt S; Brenner H
Am J Gastroenterol; 2010 Mar; 105(3):682-90. PubMed ID: 19953091
[TBL] [Abstract][Full Text] [Related]
17. Limitations of the faecal occult blood test in screening for colorectal cancer.
Delcò F; Sonnenberg A
Ital J Gastroenterol Hepatol; 1999 Mar; 31(2):119-26. PubMed ID: 10363196
[TBL] [Abstract][Full Text] [Related]
18. Psychosocial and medical predictors of colorectal cancer screening among low-income medical outpatients.
Friedman LC; Webb JA; Everett TE
J Cancer Educ; 2004; 19(3):180-6. PubMed ID: 15458875
[TBL] [Abstract][Full Text] [Related]
19. Colon cancer screening: recommendations and barriers to patient participation.
Peters DP
Nurse Pract; 2008 Dec; 33(12):14-20; quiz 21. PubMed ID: 19057341
[No Abstract] [Full Text] [Related]
20. Repeat participation in colorectal cancer screening utilizing fecal occult blood testing: a community-based project in a rural setting.
Janda M; Hughes KL; Auster JF; Leggett BA; Newman BM
J Gastroenterol Hepatol; 2010 Oct; 25(10):1661-7. PubMed ID: 20880176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
